Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

GlaxoSmithKline Pharmaceuticals stock price, quote, forecast and news

GLAXO.NS
INE159A01016

Price

2,765.40
Today +/-
+0
Today %
+0 %
P

GlaxoSmithKline Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into GlaxoSmithKline Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GlaxoSmithKline Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GlaxoSmithKline Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of GlaxoSmithKline Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into GlaxoSmithKline Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing GlaxoSmithKline Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GlaxoSmithKline Pharmaceuticals’s growth potential.

GlaxoSmithKline Pharmaceuticals Revenue, EBIT and net profit per share

DateGlaxoSmithKline Pharmaceuticals RevenueGlaxoSmithKline Pharmaceuticals EBITGlaxoSmithKline Pharmaceuticals Net Income
2027e47.24 B undefined12.33 B undefined10.35 B undefined
2026e42.97 B undefined12.03 B undefined9.58 B undefined
2025e39.06 B undefined10.5 B undefined8.42 B undefined
202434.54 B undefined8.39 B undefined5.9 B undefined
202332.52 B undefined7.49 B undefined6.11 B undefined
202232.78 B undefined6.99 B undefined16.95 B undefined
202129.26 B undefined5.2 B undefined3.58 B undefined
202032.24 B undefined5.87 B undefined932 M undefined
201931.28 B undefined5.57 B undefined4.45 B undefined
201828.96 B undefined4.78 B undefined3.51 B undefined
201730 B undefined3.94 B undefined3.37 B undefined
201628.38 B undefined4.54 B undefined3.76 B undefined
201533.05 B undefined6.1 B undefined4.76 B undefined
201325.63 B undefined5.09 B undefined4.82 B undefined
201226.47 B undefined8.1 B undefined5.62 B undefined
201124.14 B undefined7.88 B undefined4.29 B undefined
201021.53 B undefined7.43 B undefined5.61 B undefined
200919.08 B undefined6.6 B undefined5.08 B undefined
200817.26 B undefined6.11 B undefined5.91 B undefined
200716.38 B undefined5.6 B undefined5.48 B undefined
200615.82 B undefined4.96 B undefined5.51 B undefined
200515.19 B undefined4.22 B undefined5.07 B undefined
200414.1 B undefined3.75 B undefined3.38 B undefined

GlaxoSmithKline Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
200120022003200420052006200720082009201020112012201320152016201720182019202020212022202320242025e2026e2027e
11.3911.8511.3714.115.1915.8216.3817.2619.0821.5324.1426.4725.6333.0528.383028.9631.2832.2429.2632.7832.5234.5439.0642.9747.24
-4.04-4.0724.027.724.183.565.3310.5612.8412.159.62-3.1728.95-14.125.71-3.488.033.08-9.2712.05-0.806.2113.0810.019.95
43.8747.6255.1757.1957.9360.0861.1458.6359.6459.8958.2855.4450.6353.1348.8546.4252.1952.6655.5053.2454.7957.1257.81---
55.646.278.068.89.5110.0210.1211.3812.8914.0714.6712.9717.5613.8613.9315.1116.4717.915.5817.9618.5719.97000
0.81.62.373.754.224.965.66.116.67.437.888.15.096.14.543.944.785.575.875.26.997.498.3910.512.0312.33
6.9913.4920.8626.5727.8231.3534.2035.4334.6134.5032.6430.5919.8618.4716.0013.1316.4917.8118.2017.7621.3223.0224.3026.8828.0026.10
0.410.971.753.385.075.515.485.915.085.614.295.624.824.763.763.373.514.450.933.5816.956.115.98.429.5810.35
-136.1780.0692.7550.168.66-0.647.96-14.0810.38-23.5531.10-14.27-1.10-21.05-10.454.1327.00-79.07284.23373.25-63.97-3.3942.7213.788.08
--------------------------
--------------------------
149149149175172169169169169169169169169169169169169169169169169169.41169.41000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The GlaxoSmithKline Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the GlaxoSmithKline Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of GlaxoSmithKline Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand GlaxoSmithKline Pharmaceuticals's financial health and stability.

Assets

GlaxoSmithKline Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that GlaxoSmithKline Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of GlaxoSmithKline Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into GlaxoSmithKline Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2001200220032004200520062007200820092010201120122013201520162017201820192020202120222023
1.152.012.924.284.885.666.237.017.618.729.279.836.858.085.764.655.226.546.477.237.678.37
347240221217199200205163163176204178198253249263379485826792681657
0000000000000000000000
172-416-942-1,320-1,145-2,720-2,474-2,840-1,649-3,012-3,896-2,666-2,326-2,893-3,303-1,863-374-2,042-1,418-1,012-6-3,104
-990-432-357-885-445-557-773-1,033-1,011-1,086-2,227-4,201-1,912-2,059-1,317-694-499-888-976-1,232-242-1,084
10666181716663366334421541351913
0.460.70.961.451.512.312.532.461.853.143.173.182.442.522.061.612.0221.861.471.212.65
0.681.41.842.293.492.593.193.35.124.793.353.142.813.381.392.364.734.094.915.788.114.84
-266-136-153-93-233-186-153-238-303-213-425-390-582-1,631-2,323-3,044-4,033-2,912-1,583-442-346-440
0.28-0.04-1.88-1.520.71-0.010.998.276.610.873.58-1.11.891.84.993.01-1.04-1.53-0.574.19-4.068.08
0.550.1-1.72-1.420.940.171.148.516.911.084.01-0.712.473.437.316.052.991.381.024.63-3.718.52
0000000000000000000000
-281-77891062-1-2-2-2-3-4-10-7-7-6-4-150-149-156-168
0000-2,07300000000000000000
-843-546-599-999-4,440-2,691-2,984-3,553-3,948-2,971-3,948-4,406-4,941-4,969-6,383-5,107-3,066-3,583-4,276-6,961-5,242-15,433
-148.00-66.00-85.00-130.00-290.00-339.00-374.00-521.00-579.00-438.00-568.00-621.00-723.00-724.00-1,082.00-864.00-519.00-614.00-737.00-35.00-19.00-9.00
-413-403-522-879-2,086-2,358-2,612-3,030-3,366-2,530-3,376-3,781-4,213-4,235-5,293-4,235-2,541-2,964-3,388-6,776-5,066-15,255
0.120.82-0.64-0.23-0.24-0.121.198.027.772.692.99-2.37-0.240.21-00.260.62-1.020.063-1.19-2.51
413.61,265.71,6852,196.53,259.92,399.73,0353,061.54,811.44,579.72,928.32,745.12,230.91,745.2-934.2-684.3694.21,182.13,321.25,3377,761.14,401.86
0000000000000000000000

GlaxoSmithKline Pharmaceuticals stock margins

The GlaxoSmithKline Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GlaxoSmithKline Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GlaxoSmithKline Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the GlaxoSmithKline Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the GlaxoSmithKline Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the GlaxoSmithKline Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the GlaxoSmithKline Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GlaxoSmithKline Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GlaxoSmithKline Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GlaxoSmithKline Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

GlaxoSmithKline Pharmaceuticals Margin History

GlaxoSmithKline Pharmaceuticals Gross marginGlaxoSmithKline Pharmaceuticals Profit marginGlaxoSmithKline Pharmaceuticals EBIT marginGlaxoSmithKline Pharmaceuticals Profit margin
2027e57.81 %26.1 %21.92 %
2026e57.81 %28 %22.3 %
2025e57.81 %26.88 %21.56 %
202457.81 %24.3 %17.08 %
202357.12 %23.02 %18.78 %
202254.79 %21.32 %51.7 %
202153.24 %17.76 %12.24 %
202055.5 %18.2 %2.89 %
201952.66 %17.81 %14.24 %
201852.19 %16.49 %12.11 %
201746.42 %13.13 %11.23 %
201648.85 %16 %13.25 %
201553.13 %18.47 %14.42 %
201350.63 %19.86 %18.8 %
201255.44 %30.59 %21.23 %
201158.28 %32.64 %17.75 %
201059.89 %34.5 %26.04 %
200959.64 %34.61 %26.62 %
200858.63 %35.43 %34.25 %
200761.14 %34.2 %33.42 %
200660.08 %31.35 %34.83 %
200557.93 %27.82 %33.39 %
200457.19 %26.57 %23.96 %

GlaxoSmithKline Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The GlaxoSmithKline Pharmaceuticals earnings per share therefore indicates how much revenue GlaxoSmithKline Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GlaxoSmithKline Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GlaxoSmithKline Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GlaxoSmithKline Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GlaxoSmithKline Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

GlaxoSmithKline Pharmaceuticals Revenue, EBIT and net profit per share

DateGlaxoSmithKline Pharmaceuticals Sales per ShareGlaxoSmithKline Pharmaceuticals EBIT per shareGlaxoSmithKline Pharmaceuticals Earnings per Share
2027e278.86 undefined0 undefined61.12 undefined
2026e253.62 undefined0 undefined56.55 undefined
2025e230.54 undefined0 undefined49.7 undefined
2024203.87 undefined49.53 undefined34.83 undefined
2023191.95 undefined44.19 undefined36.05 undefined
2022193.96 undefined41.36 undefined100.28 undefined
2021173.11 undefined30.75 undefined21.19 undefined
2020190.79 undefined34.73 undefined5.51 undefined
2019185.09 undefined32.97 undefined26.36 undefined
2018171.34 undefined28.25 undefined20.75 undefined
2017177.51 undefined23.31 undefined19.93 undefined
2016167.92 undefined26.88 undefined22.25 undefined
2015195.53 undefined36.11 undefined28.19 undefined
2013151.64 undefined30.11 undefined28.5 undefined
2012156.61 undefined47.91 undefined33.25 undefined
2011142.86 undefined46.63 undefined25.36 undefined
2010127.38 undefined43.95 undefined33.17 undefined
2009112.89 undefined39.07 undefined30.05 undefined
2008102.11 undefined36.17 undefined34.98 undefined
200796.94 undefined33.15 undefined32.4 undefined
200693.61 undefined29.34 undefined32.6 undefined
200588.28 undefined24.56 undefined29.48 undefined
200480.55 undefined21.41 undefined19.3 undefined

GlaxoSmithKline Pharmaceuticals business model

GlaxoSmithKline (GSK) is a global pharmaceutical company focused on the development, manufacturing, and marketing of prescription medicines, vaccines, and consumer products. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, the company has become one of the leading players in the pharmaceutical and healthcare industry. GSK's history began in 1859 with the opening of a pharmacy in New Zealand by Joseph Edward Nathan. In 1904, physician and researcher Joseph Nathan Cohen founded Glaxo Laboratories, which specialized in the production of vitamin preparations. Over the years, the company expanded and eventually merged with Wellcome plc in 1995 to form Glaxo Wellcome. SmithKline Beecham was founded in 1830 and expanded through acquisitions and mergers in the following decades. In June 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline. GSK's business model is based on research, development, and marketing of products aimed at improving patients' lives. The company has a wide range of products, including prescription medicines, vaccines, and consumer products. GSK operates in over 100 countries and employs over 100,000 people worldwide. GSK has various divisions, including pharmaceuticals, vaccines, and consumer healthcare. The pharmaceutical division is the company's core business and focuses on researching and developing innovative therapies in the areas of oncology, immunology, infectious diseases, and respiratory diseases. The company's vaccine division is involved in vaccine production and the development of new vaccine technologies. GSK is one of the largest vaccine manufacturers globally and produces vaccines against infectious diseases such as hepatitis A and B, meningococcal disease, pneumococcal disease, and HPV. The company's consumer healthcare division produces a wide range of products in the health and wellness sector, including dietary supplements, pain relievers, and skincare products under brands like Sensodyne, Voltaren, and Aquafresh. Some of GSK's most well-known products include the antidepressant Paxil, the asthma inhaler Advair, and the antimalarial medication Malarone. Additionally, GSK has played a leading role in addressing global health issues, such as developing a vaccine against Ebola and providing antiretroviral drugs for the treatment of HIV/AIDS. Overall, GlaxoSmithKline has established a strong position as one of the leading global pharmaceutical companies in recent years. The company pursues an innovative research and development strategy to promote forward-looking technologies that have the potential to change the way we perceive and treat diseases. With a strong focus on innovation, growth, and improving the quality of life for patients worldwide, GSK is on track to remain a significant player in the global healthcare industry. GlaxoSmithKline Pharmaceuticals is one of the most popular companies on Eulerpool.com.

GlaxoSmithKline Pharmaceuticals SWOT Analysis

Strengths

GlaxoSmithKline Pharmaceuticals Ltd is a leading pharmaceutical company globally, benefiting from its strong brand reputation, extensive product portfolio, and research and development capabilities. The company has a diversified revenue stream, with a focus on high-demand therapeutic areas such as respiratory, vaccines, and oncology. GSK's strong global presence and well-established distribution networks enable it to reach a wide consumer base and increase market share. Additionally, the company has a long history of successful mergers and acquisitions, contributing to its overall strength in the industry.

Weaknesses

Despite its strengths, GlaxoSmithKline Pharmaceuticals Ltd faces certain weaknesses. The company has experienced declining sales in some key markets due to generic competition and patent expirations. GSK has faced criticism for its pricing strategies and ethical controversies in the past, which has affected its brand reputation. Furthermore, its heavy reliance on a few blockbuster drugs poses a risk to its revenue stream, as any setbacks or regulatory issues can significantly impact the company's financial performance.

Opportunities

GlaxoSmithKline Pharmaceuticals Ltd has ample opportunities to capitalise on market trends and advancements in the healthcare industry. The rising demand for healthcare products and services, especially in emerging markets, presents an opportunity for GSK to expand its market reach and increase sales. The company can further invest in developing innovative drugs, leveraging its strong research and development capabilities, to address unmet medical needs. Collaborations and partnerships with other healthcare organizations, as well as digital transformation, can also open new avenues for growth.

Threats

There are several external threats that GlaxoSmithKline Pharmaceuticals Ltd should be aware of. Intense competition from other pharmaceutical companies, both established players and emerging market entrants, poses a threat to GSK's market share. Increasing regulatory scrutiny and changing healthcare policies can impact the company's operations and profitability. Moreover, the potential threats of counterfeit drugs, global economic uncertainties, and geopolitical issues in key markets could disrupt GSK's supply chain and have adverse effects on its business performance.

GlaxoSmithKline Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

GlaxoSmithKline Pharmaceuticals shares outstanding

The number of shares was GlaxoSmithKline Pharmaceuticals in 2023 — This indicates how many shares 169.406 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GlaxoSmithKline Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GlaxoSmithKline Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GlaxoSmithKline Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GlaxoSmithKline Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

GlaxoSmithKline Pharmaceuticals Stock splits

In GlaxoSmithKline Pharmaceuticals's history, there have been no stock splits.

GlaxoSmithKline Pharmaceuticals dividend history and estimates

In 2023, GlaxoSmithKline Pharmaceuticals paid a dividend amounting to 32 INR. Dividend means that GlaxoSmithKline Pharmaceuticals distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for GlaxoSmithKline Pharmaceuticals provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify GlaxoSmithKline Pharmaceuticals’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating GlaxoSmithKline Pharmaceuticals's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

GlaxoSmithKline Pharmaceuticals Dividend History

DateGlaxoSmithKline Pharmaceuticals Dividend
2027e27.99 undefined
2026e25.01 undefined
2025e30.32 undefined
202432 undefined
202332 undefined
202230 undefined
202130 undefined
202020 undefined
201920 undefined
201817.5 undefined
201715 undefined
201625 undefined
201531.25 undefined
201325 undefined
201222.5 undefined
201120 undefined
201015 undefined
200911 undefined
20089 undefined
20078.5 undefined
20067 undefined
20056.5 undefined
20045 undefined

GlaxoSmithKline Pharmaceuticals dividend payout ratio

In 2023, GlaxoSmithKline Pharmaceuticals had a payout ratio of 178.18%. The payout ratio indicates the percentage of the company's profits that GlaxoSmithKline Pharmaceuticals distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for GlaxoSmithKline Pharmaceuticals represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for GlaxoSmithKline Pharmaceuticals could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate GlaxoSmithKline Pharmaceuticals's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

GlaxoSmithKline Pharmaceuticals Payout Ratio History

DateGlaxoSmithKline Pharmaceuticals Payout ratio
2027e119.71 %
2026e134.33 %
2025e108.23 %
2024116.58 %
2023178.18 %
202229.92 %
2021141.64 %
2020362.98 %
201975.9 %
201884.34 %
201775.3 %
2016112.36 %
2015110.89 %
201387.72 %
201267.69 %
201178.86 %
201045.22 %
200936.61 %
200825.74 %
200726.24 %
200621.47 %
200522.05 %
200425.92 %
Unfortunately, there are currently no price targets and forecasts available for GlaxoSmithKline Pharmaceuticals.

GlaxoSmithKline Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/202311.63 7.88  (-32.24 %)2023 Q4
12/31/20229.37 9.71  (3.6 %)2023 Q3
9/30/202210.32 11.42  (10.65 %)2023 Q2
6/30/20228.39 7.04  (-16.14 %)2023 Q1
3/31/202210.64 71.96  (576.32 %)2022 Q4
12/31/20219.53 8.88  (-6.8 %)2022 Q3
9/30/20218.75 11.96  (36.69 %)2022 Q2
3/31/20219.52 7.87  (-17.31 %)2021 Q4
3/31/20207.93 7.44  (-6.19 %)2020 Q4
1

Eulerpool ESG Scorecard© for the GlaxoSmithKline Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

65/ 100

🌱 Environment

68

👫 Social

71

🏛️ Governance

56

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees11
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

GlaxoSmithKline Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
75.00 % Glaxo Group, Ltd.127,054,524012/31/2023
2.28 % Life Insurance Corporation of India3,869,950-1,091,82312/31/2023
1.27 % ICICI Prudential Asset Management Co. Ltd.2,157,098-1,951,74612/31/2023
1.03 % Aditya Birla Sun Life AMC Limited1,738,128-213/31/2024
0.99 % Nippon Life India Asset Management Limited1,678,804-80,0973/31/2024
0.76 % The Vanguard Group, Inc.1,285,982-33,4603/31/2024
0.58 % Investor Education Protection Fund986,485-4,22812/31/2023
0.58 % Kotak Mahindra Asset Management Company Limited976,715242,0933/31/2024
0.51 % Quant Money Managers Ltd860,00003/31/2024
0.48 % SBI Funds Management Pvt. Ltd.812,1162363/31/2024
1
2
3
4
5
...
8

GlaxoSmithKline Pharmaceuticals Executives and Management Board

Mr. Juby Chandy46
GlaxoSmithKline Pharmaceuticals Chief Financial Officer, Whole Time Director (since 2022)
Compensation 54.13 M
Mr. Bhushan Akshikar
GlaxoSmithKline Pharmaceuticals Managing Director, Executive Director (since 2022)
Compensation 26.08 M
Mr. Ajay Nadkarni
GlaxoSmithKline Pharmaceuticals Vice President - Administration, Real Estate, Company Secretary (since 2022)
Compensation 17.15 M
Ms. Renu Karnad71
GlaxoSmithKline Pharmaceuticals Non-Executive Chairman of the Board
Compensation 3.55 M
Mr. Damodarannair Sundaram68
GlaxoSmithKline Pharmaceuticals Non-Executive Independent Director
Compensation 2.9 M
1
2
3
4
...
5

Most common questions regarding GlaxoSmithKline Pharmaceuticals

What values and corporate philosophy does GlaxoSmithKline Pharmaceuticals represent?

GlaxoSmithKline Pharmaceuticals Ltd represents values and a corporate philosophy centered on innovation, integrity, and patient-focused healthcare. As a leading pharmaceutical company, GlaxoSmithKline is committed to discovering, developing, and delivering high-quality medicines that improve people's lives. Their philosophy revolves around ethical business practices, stringent quality standards, and adherence to regulatory norms. By leveraging cutting-edge research and technology, GlaxoSmithKline aims to address critical healthcare challenges and contribute to societal well-being. With a strong emphasis on sustainability, they are dedicated to reducing environmental impact and promoting responsible business practices. GlaxoSmithKline Pharmaceuticals Ltd's relentless pursuit of scientific excellence and commitment to serving patients underscores their reputation as a trusted and renowned pharmaceutical entity.

In which countries and regions is GlaxoSmithKline Pharmaceuticals primarily present?

GlaxoSmithKline Pharmaceuticals Ltd is primarily present in various countries and regions. The company has a strong global presence and operates in multiple markets. Some of the key countries where GlaxoSmithKline Pharmaceuticals Ltd has a significant presence include the United Kingdom, United States, India, China, Japan, Australia, the European Union, and many more. With its extensive reach, GlaxoSmithKline Pharmaceuticals Ltd continues to expand its operations and serve customers in diverse geographical locations.

What significant milestones has the company GlaxoSmithKline Pharmaceuticals achieved?

GlaxoSmithKline Pharmaceuticals Ltd has achieved several significant milestones. Notably, the company has consistently demonstrated its commitment to innovation and has been at the forefront of discovering and developing life-saving medications. With a strong focus on research and development, GlaxoSmithKline Pharmaceuticals Ltd has successfully launched numerous breakthrough drugs that have revolutionized healthcare. Additionally, the company has maintained a stellar track record in ensuring high-quality and affordable pharmaceutical products for patients across the globe. With its unwavering dedication to advancing healthcare, GlaxoSmithKline Pharmaceuticals Ltd continues to achieve remarkable milestones in improving the overall well-being of people worldwide.

What is the history and background of the company GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals Ltd, a leading pharmaceutical company, has a rich history and background. Established in 1924, it has evolved into a trusted healthcare provider. GlaxoSmithKline Pharmaceuticals specializes in the research, development, and manufacturing of innovative medicines and vaccines. With a strong presence in India, it has played a pivotal role in the country's healthcare sector. As a subsidiary of GlaxoSmithKline plc, a global pharmaceutical company, it benefits from the extensive expertise and resources of its parent company. GlaxoSmithKline Pharmaceuticals is dedicated to enhancing the quality of life and contributing to the well-being of individuals through its cutting-edge healthcare solutions.

Who are the main competitors of GlaxoSmithKline Pharmaceuticals in the market?

The main competitors of GlaxoSmithKline Pharmaceuticals Ltd in the market are Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, and Cipla Ltd.

In which industries is GlaxoSmithKline Pharmaceuticals primarily active?

GlaxoSmithKline Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

What is the business model of GlaxoSmithKline Pharmaceuticals?

The business model of GlaxoSmithKline Pharmaceuticals Ltd is focused on the research, development, manufacturing, and marketing of pharmaceutical products. As a leading pharmaceutical company, GlaxoSmithKline Pharmaceuticals Ltd produces a wide range of medicines across various therapeutic areas, including respiratory, anti-infective, dermatology, and more. The company aims to improve the quality of human life by delivering innovative and high-quality healthcare solutions. With a strong commitment to research and development, GlaxoSmithKline Pharmaceuticals Ltd strives to address unmet medical needs and provide accessible and affordable healthcare options to patients worldwide.

What is the P/E ratio of GlaxoSmithKline Pharmaceuticals 2024?

The GlaxoSmithKline Pharmaceuticals P/E ratio is 79.41.

What is the P/S ratio of GlaxoSmithKline Pharmaceuticals 2024?

The GlaxoSmithKline Pharmaceuticals P/S ratio is 13.56.

What is the AlleAktien quality score of GlaxoSmithKline Pharmaceuticals?

The AlleAktien quality score for GlaxoSmithKline Pharmaceuticals is 9/10.

What is the revenue of GlaxoSmithKline Pharmaceuticals 2024?

The GlaxoSmithKline Pharmaceuticals revenue is 34.54 B INR.

How high is the profit of GlaxoSmithKline Pharmaceuticals 2024?

The GlaxoSmithKline Pharmaceuticals profit is 5.9 B INR.

What is the business model of GlaxoSmithKline Pharmaceuticals

The company GlaxoSmithKline Pharmaceuticals Ltd is a global company that manufactures and distributes various health products and pharmaceuticals. It was founded in 2000 through the merger of the British pharmaceutical company GlaxoWellcome and the American corporation SmithKline Beecham. The business model of GlaxoSmithKline Pharmaceuticals is based on the production of prescription and over-the-counter medications for various therapeutic areas. The company is divided into three divisions: Pharma, Vaccines, and Consumer Healthcare. In the Pharma division, GlaxoSmithKline manufactures innovative medications for areas such as oncology, diabetes, and respiratory diseases. These are primarily prescription drugs prescribed by doctors. The Vaccine division develops and produces vaccines for different infectious diseases such as meningitis or HPV. Consumer Healthcare, on the other hand, offers over-the-counter medications for colds, pain, and gastrointestinal issues. Some of the well-known medications produced by GlaxoSmithKline Pharmaceuticals include Zovirax (for herpes), Advair (for asthma), Voltaren (for pain), and Panadol (for pain and fever). The company also has products for HIV/AIDS therapy, such as Tivicay. In the Vaccine division, the company offers products such as Hepatitis A and B vaccines, the HPV vaccine Cervarix, and the pneumococcal vaccine Synflorix. Consumer Healthcare distributes over-the-counter products such as Otrivin (for nasal congestion), Nicorette (for smoking cessation), and Sensodyne (for sensitive teeth). The company continuously invests in research and development to develop new medications and improve existing products. In 2019, GlaxoSmithKline Pharmaceuticals' research and development budget was almost 4 billion euros. Additionally, the company works closely with government agencies and other partners to combat global health issues. For example, GlaxoSmithKline Pharmaceuticals is involved in an immunization program for children in developing countries. The company distributes its products worldwide, operating in more than 150 countries. The company's headquarters are located in Brentford, United Kingdom. It also has a presence in Germany, with a location in Munich. In summary, GlaxoSmithKline Pharmaceuticals Ltd is a leading company in the pharmaceutical and healthcare products industry. Its business model is based on the production of prescription and over-the-counter medications as well as vaccines. The company's close collaboration with government agencies and partners makes it an important player in the fight against global health issues.

What is the GlaxoSmithKline Pharmaceuticals dividend?

GlaxoSmithKline Pharmaceuticals pays a dividend of 30 INR distributed over payouts per year.

How often does GlaxoSmithKline Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for GlaxoSmithKline Pharmaceuticals or the company does not pay out a dividend.

What is the GlaxoSmithKline Pharmaceuticals ISIN?

The ISIN of GlaxoSmithKline Pharmaceuticals is INE159A01016.

What is the GlaxoSmithKline Pharmaceuticals ticker?

The ticker of GlaxoSmithKline Pharmaceuticals is GLAXO.NS.

How much dividend does GlaxoSmithKline Pharmaceuticals pay?

Over the past 12 months, GlaxoSmithKline Pharmaceuticals paid a dividend of 32 INR . This corresponds to a dividend yield of about 1.16 %. For the coming 12 months, GlaxoSmithKline Pharmaceuticals is expected to pay a dividend of 30.32 INR.

What is the dividend yield of GlaxoSmithKline Pharmaceuticals?

The current dividend yield of GlaxoSmithKline Pharmaceuticals is 1.16 %.

When does GlaxoSmithKline Pharmaceuticals pay dividends?

GlaxoSmithKline Pharmaceuticals pays a quarterly dividend. This is distributed in the months of August, August, July, June.

How secure is the dividend of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals paid dividends every year for the past 23 years.

What is the dividend of GlaxoSmithKline Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 30.32 INR are expected. This corresponds to a dividend yield of 1.11 %.

In which sector is GlaxoSmithKline Pharmaceuticals located?

GlaxoSmithKline Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline Pharmaceuticals from 7/1/2024 amounting to 32 INR, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.

When did GlaxoSmithKline Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of GlaxoSmithKline Pharmaceuticals in the year 2023?

In the year 2023, GlaxoSmithKline Pharmaceuticals distributed 32 INR as dividends.

In which currency does GlaxoSmithKline Pharmaceuticals pay out the dividend?

The dividends of GlaxoSmithKline Pharmaceuticals are distributed in INR.

All fundamentals about GlaxoSmithKline Pharmaceuticals

Our stock analysis for GlaxoSmithKline Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.